ReviewVirchows Archiv : an international journal of pathology2014
Prognostic biomarkers in endometrial and ovarian carcinoma.
Review in Virchows Archiv : an international journal of pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic value of circulating tumor cells and disseminated tumor cells in patients with ovarian cancer: a systematic review and meta-analysis.Journal of ovarian research · 2015Pooled it
- Molecular features for timely cancer diagnosis and treatment - tumors of the ovary, fallopian tube and endometrium.Virchows Archiv : an international journal of pathology · 2024Review
- Could Argyrophilic Nucleolar Organizer Regions count mirror DNA Ploidy in Malignant Salivary Gland Tumors?Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Autophagy in the physiological endometrium and cancer.Autophagy · 2021Review
- Comprehensive Analysis of Prognostic Alternative Splicing Signatures in Endometrial Cancer.Frontiers in genetics · 2020Article
- Unsupervised Clustering of Immunohistochemical Markers to Define High-Risk Endometrial Cancer.Pathology oncology research : POR · 2019Article
- Mitochondrial functions and melatonin: a tour of the reproductive cancers.Cellular and molecular life sciences : CMLS · 2019Review
- International Society of Gynecological Pathologists (ISGyP) Endometrial Cancer Project: Guidelines From the Special Techniques and Ancillary Studies Group.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2019Article
- Expression of P-REX2a is associated with poor prognosis in endometrial malignancies.Oncotarget · 2018Article
- Article
- PAX8 is a potential marker for the diagnosis of primary epithelial ovarian cancer.Oncology letters · 2017Article
- The Potential Roles of MELF-Pattern, Microvessel Density, and VEGF Expression in Survival of Patients with Endometrioid Endometrial Carcinoma: A Morphometrical and Immunohistochemical Analysis of 100 Cases.Journal of pathology and translational medicine · 2017Article
- Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile.European journal of clinical pharmacology · 2016Article
- Revisiting tumour aneuploidy - the place of ploidy assessment in the molecular era.Nature reviews. Clinical oncology · 2016Review
- Mitochondrial ribosomal protein S18-2 is highly expressed in endometrial cancers along with free E2F1.Oncotarget · 2016Article
- Molecular staging of gynecological cancer: What is the future?Best practice & research. Clinical obstetrics & gynaecology · 2015Review
- Clinical significance of Sam68 expression in endometrial carcinoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Enhancer of zeste homolog 2 is involved in the proliferation of endometrial carcinoma.Oncology letters · 2014Article
- Prognostic biomarkers: an introduction.Virchows Archiv : an international journal of pathology · 2014Article
- Identification of two poorly prognosed ovarian carcinoma subtypes associated with CHEK2 germ-line mutation and non-CHEK2 somatic mutation gene signatures.Cell cycle (Georgetown, Tex.) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This article reviews the main prognostic and predictive biomarkers of endometrial (EC) and ovarian carcinoma (OC). In EC, prognosis still relies on conventional pathological features such as histological type and grade, as well as myometrial or lymphovascular space invasion. Estrogen receptor, p53, Ki-67, and ploidy analysis are the most promising biomarkers among a long list of molecules that have been proposed. Also, a number of putative predictive biomarkers have been proposed in molecular targeted therapy. In OC, prognosis is predominantly dependent on disease stage at diagnosis and the extent of residual disease at primary operation. Diagnostic markers which aid in establishing histological type in OC are available. However, not a single universally accepted predictive or prognostic marker exists to date. Targeted therapy has been growingly focused at in recent years, in view of the frequent development of chemoresistance at recurrent disease. The present review emphasizes the crucial role of correct pathological classification and stringent selection criteria of the material studied as basis for any evaluation of biological markers. It further emphasizes the promise of targeted therapy in EC and OC, while simultaneously highlighting the difficulties remaining before this can become standard of care.
Indexed as
Identifiers
24504546What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.